...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Rheumatology >Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: Long-term safety and survival using prospective, observational data
【24h】

Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: Long-term safety and survival using prospective, observational data

机译：使用依那西普治疗风湿性关节炎并参考可改变疾病的抗风湿药：使用前瞻性和观察性数据的长期安全性和生存率

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective. The objective of this study was to examine the long-term safety of etanercept (ETN) in comparison with conventional DMARDs in a large observational cohort of RA patients in the UK. Methods. Data were made available from the British Society of Rheumatology Biologics Register for a cohort of patients with RA treated with ETN and a reference cohort of RA patients treated with conventional DMARDs (maximum follow-up 10 years). The adjusted risk of events was compared using Cox proportional hazards models. Results. There were 3529 eligible ETN-treated patients (16 919 person-years) and 2864 conventional DMARD-treated patients (11 095 person-years), with notable differences between groups at baseline. Crude mortality rates were 12.0 vs 20.1 events per 1000 person-years for ETN and conventional DMARD patients, respectively, with an adjusted hazard ratio (aHR) of 0.72 (95% CI 0.54, 0.96). There was no difference in the long-term risk of serious infections (aHR = 1.02, 95% CI 0.83, 1.25). However, the risk was increased for ETN in the first 2 years (aHR = 1.56, 95% CI 1.16, 2.09; aHR = 1.32, 95% CI 1.06, 1.65). The aHRs (95% CIs) of various outcomes were cancer, 0.84 (0.68, 1.03); lymphoproliferative malignancy specifically, 0.51 (0.28, 0.95); all other serious adverse events, 0.70 (0.56, 0.87) and cardiac events specifically, 0.52 (0.37, 0.72). Conclusion. There was no evidence of adverse outcome from long-term exposure to ETN. There was evidence of improved survival, reduced cardiovascular events and reduced lymphoproliferative malignancies.
机译：目的。这项研究的目的是在英国的大量RA观察人群中研究依那西普（ETN）与常规DMARDs的长期安全性。方法。数据可从英国风湿病生物学学会注册，获得接受ETN治疗的RA患者和接受常规DMARD治疗的RA患者的参考队列（最长随访10年）。使用Cox比例风险模型比较了调整后的事件风险。结果。有3529名合格的ETN治疗患者（16 919人年）和2864名常规DMARD治疗患者（11 095人年），基线时两组之间存在显着差异。 ETN和常规DMARD患者的粗死亡率分别为每1000人年12.0和20.1事件，调整后的危险比（aHR）为0.72（95％CI 0.54，0.96）。严重感染的长期风险没有差异（aHR = 1.02，95％CI 0.83，1.25）。但是，在头2年中，ETN的风险有所增加（aHR = 1.56，95％CI 1.16，2.09; aHR = 1.32，95％CI 1.06，1.65）。各种结局的aHR（95％CI）为癌症，为0.84（0.68，1.03）;淋巴增生性恶性肿瘤具体为0.51（0.28，0.95）;所有其他严重不良事件为0.70（0.56，0.87），而心脏事件为0.52（0.37，0.72）。结论。没有证据表明长期暴露于ETN中会导致不良后果。有证据表明生存率提高，心血管事件减少和淋巴组织增生性恶性肿瘤减少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号